Bendamustine associated immune suppression and infections during therapy of hematological malignancies

Leukemia and Lymphoma

Volumn 57, Issue 3, 2016, Pages 512-519

  Gafter Gvili, Anat ^a,b   Polliack, Aaron ^c  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

Bendamustine; Chemotherapy; Hematological malignancies; Immune suppression; Infections

Indexed keywords

ANTIBIOTIC AGENT; BENDAMUSTINE; RITUXIMAB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION PREVENTION; INFECTION RATE; LYMPHOCYTOPENIA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MYCOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T CELL DEPLETION; VIRUS INFECTION; AGAMMAGLOBULINEMIA; COMPLICATION; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; LYMPHOPENIA;

AGAMMAGLOBULINEMIA; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENDAMUSTINE HYDROCHLORIDE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; INFECTION; LYMPHOPENIA;

EID: 84951284248     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1110748     Document Type: Review

References (58)

1. Korycka-Wolowiec A, Robak T. Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opin Drug Metab Toxicol 2012; 8: 1455-1468.
2. Tageja N. Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma. Clin Med Insights Oncol 2011; 5: 145-156.
3. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309-317.
4. Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010; 10: 21-27.
5. Cheson BD, Brugger W, Damaj G, et al. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel-an update. Leuk Lymphoma 2015, in press.
6. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210.
7. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010; 116: 106-114.
8. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26: 204-210.
9. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006; 132: 105-112.
10. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378-4384.
11. Niederle N, Megdenberg D, Balleisen L, et al. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol 2013; 92: 653-660.
12. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29: 3559-3566.
13. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132: 205-212.
14. Brugger W, Ghielmini M. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management. Oncologist 2013; 18: 954-964.
15. Cheson BD, Friedberg JW, Kahl BS, et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10: 452-457.
16. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123: 2944-2952.
17. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011; 103: 1799-1806.
18. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-2045.
19. Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009; 114: 4713-4720.
20. Yang ZZ, Novak AJ, Stenson MJ, et al. Intratumoral CD4 + CD25 + regulatory T-cell-mediated suppression of infiltrating CD4 + T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639-3646.
21. Hosoda T, Yokoyama A, Yoneda M, et al. Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma 2013; 54: 1327-1328.
22. Saito HMD, Maeshima A, Makita S, et al. Prolonged lymphocytepenia after bendamustine with or without rituximab treatment in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood 2014; 124: 3066.
23. Schoffski P, Seeland G, Engel H, et al. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol 2000; 11: 729-734.
24. Ito K, Okamoto M, Ando M, et al. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. Leuk Lymphoma 2015; 56: 1123-1125.
25. Garcia Munoz R, Izquierdo-Gil A, Munoz A, et al. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol 2014; 93: 1879-1887.
26. Yutaka T, Ito S, Ohigashi H, et al. Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma. Leuk Lymphoma 2015; 56: 1-3.
27. Burchardt ABM, Rummel M, Sandherr M. Immunochemotherapy with bendamustine-rituximab (BR) as induction therapy for indolent lymphomas results in a severe lympopenia with low CD4 + and CD8 + counts without an increase in atypical infections. First results of the infectious disease (ID) project of a prospective, randomized, multicenter study (STIL NHL 7-2008, MAINTAIN; NCT00877214. Hematol Oncol 2013; 31: 96-150.
28. Gafter-Gvili A, Ribakovsky E, Mizrahi N, et al. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. Leuk Lymphoma 2015; 56: 1-7.
29. Layman RM, Ruppert AS, Lynn M, et al. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol 2013; 71: 1183-1190.
30. Besada E, Nossent JC. Infection risks during longterm rituximab therapy change over time. J Rheumatol 2013; 40: 203.
31. Melet J, Mulleman D, Goupille P, et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum 2013; 65: 2783-2790.
32. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013; 13: 106-111.
33. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood 2004; 103: 4416-4423.
34. Takada K, Danning CL, Kuroiwa T, et al. Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects. Ann Rheum Dis 2003; 62: 1112-1115.
35. Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006; 17: 1424-1427.
36. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694-704.
37. Rummel MJ, Kaiser U, Böck H, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent, or mantle cell lymphomas-8-year follow-up results of the randomized phase III study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 2014; 124: 145.
38. Eichhorst BFA, Busch R, Kovacs G, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood (Suppl) 2014; 124.
39. Leblond VLK, Ilhan O, Aktan M, et al. Rituximab in combination with bendamustine or chlorambucil for treating patients with chronic lymphocytic leukemia: interim results of a phase IIIb study (MaBLe). Blood (Suppl) 2012; 120: 2744
40. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473-4479.
41. Zaja F, Mian M, Volpetti S, et al. Bendamustine in chronic lymphocytic leukemia: outcome accorDing to different clinical and biological prognostic factors in the everyday clinical practice. Am J Hematol 2013; 88: 955-960.
42. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008; 26: 4784-4790.
43. Kowal M, Dmoszynska A, Lewandowski K, et al. Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study. Leuk Lymphoma 2004; 45: 1159-1165.
44. Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001; 19: 3611-3621.
45. Merchionne F, Quintana G, Gaudio F, et al. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. Leuk Res 2014; 38: 1446-1450.
46. Lim SH, Pathapati S, Langevin J, et al. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol 2012; 91: 643-644.
47. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4: 599-608.
48. Tsutsumi Y, Ogasawara R, Miyashita N, et al. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine. Int J Hematol 2012; 95: 588-591.
49. Lock G, Helmich F, Bertram M. [ImpenDing liver failure after chemoimmunotherapy-induced reactivation of hepatitis B-successful treatment with entecavir]. Dtsch Med Wochenschr 2012; 137: 1248-1250.
50. Warsch S, Hosein PJ, Morris MI, et al. Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab. Int J Hematol 2012; 96: 274-278.
51. Lane MA, Renga V, Pachner AR, et al. Late occurrence of PML in a patient treated for lymphoma with immunomodulatory chemotherapies, bendamustine, rituximab, and ibritumomab tiuxetan. Case Rep Neurol Med 2015; 2015: 892047.
52. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816-824.
53. Carter SJ, Bernstein SH, Friedberg JW, Barr PM. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res 2011; 35: e223-e224.
54. Reinbolt RE, Alam S, Layman R, et al. Pneumocystis jiroveci pneumonia in an atypical host. Clin Breast Cancer 2012; 12: 138-141.
55. Klippstein A, Schneider CP, Sayer HG, et al. Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol 2003; 129: 316-319.
56. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012; 1: CD004386.
57. Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014; 10: CD005590.
58. Neumann S, Krause SW, Maschmeyer G, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2013; 92: 433-442.